PTC Therapeutics, Inc. (PTCT)

Market Cap	4.92B
Revenue (ttm)	1.76B
Net Income (ttm)	629.17M
Shares Out	79.44M
EPS (ttm)	7.72
PE Ratio	7.86
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	412,225
Open	60.55
Previous Close	60.65
Day's Range	59.20 - 61.98
52-Week Range	33.88 - 62.18
Beta	0.53
Analysts	Buy
Price Target	67.00 (+8.24%)
Earnings Date	Nov 6, 2025

About PTCT

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. I...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 20, 2013
• Employees: 939
• Stock Exchange: NASDAQ
• Ticker Symbol: PTCT
• Website: https://www.ptcbio.com

Financial Performance

In 2024, PTC Therapeutics's revenue was $806.78 million, a decrease of -13.97% compared to the previous year's $937.82 million. Losses were -$363.30 million, -42.02% less than in 2023.

Analyst Summary

According to 14 analysts, the average rating for PTCT stock is "Buy." The 12-month stock price target is $67.0, which is an increase of 8.24% from the latest price.

Price Target

$67.0

(8.24% upside)

Analyst Consensus: Buy